From curiosity to collaboration - Impetus Forum, where knowledge blossoms.
Recently, Kexing Biopharm announced an important milestone in its overseas commercialization strategy. Its internationally marketed drug—Paclitaxel for Injection (Albumin-bound) (brand name: Apexelsin®)—has officially received marketing approval from the Philippine Food and Drug Administration (FDA).
Compared with conventional paclitaxel injections and liposomal paclitaxel formulations, albumin-bound paclitaxel demonstrates significant clinical advantages, including:
Improved safety profile
Better patient compliance
Strong clinical recognition
Indispensable value in oncology treatment
These advantages make it an increasingly important option in cancer therapy worldwide.
As a major pharmaceutical market in Southeast Asia, the Philippines has experienced rising demand in recent years for high-quality medicines.
The approval of Apexelsin® will now provide local cancer patients with a new and important treatment option, further improving access to advanced oncology therapies.
Since obtaining marketing authorization in the European Union in 2024, Apexelsin® has been accelerating its global rollout. Over the past two years, it has received approvals in multiple countries and regions, including:
United Kingdom
Peru
Uruguay
Argentina
Oman
Malaysia
Macao, China
These approvals have helped establish a broad global sales network spanning:
👉 Europe
👉 Latin America
👉 Southeast Asia
👉 Middle East
Looking ahead, Kexing Biopharm will continue working with global partners to further improve access to high-quality medicines and expand the availability of advanced treatment options worldwide.
https://www.kexingbiopharm.com/
Kexing Biopharm
